GlassScriptPhysician profile
Noman Rafique
NPI 1043215676
$17,336.73
in general payments reported to CMS, 2019-2025
95 companies · $4,597 in 2025
The $4,597 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,408 · 2020: $881 · 2021: $556 · 2022: $3,054 · 2023: $2,971 · 2024: $2,869 · 2025: $4,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,090 · Consulting Fee: $1,320 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,090.42 |
| Consulting Fee | $1,320.00 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,854.24 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $1,550.03 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,075.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,072.47 | 2019-2025 | Keytruda, Reblozyl, Lynparza |
| Astrazeneca Pharmaceuticals LP | $729.08 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Eisai INC. | $703.06 | 2019-2025 | |
| Pfizer INC. | $655.81 | 2019-2025 | |
| Celgene Corporation | $556.18 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $512.65 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $506.35 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $456.46 | 2019-2025 | Polivy, Itovebi, Lunsumio |
| Astellas Pharma US INC | $454.17 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Amgen INC. | $422.39 | 2019-2023 | Kyprolis, Blincyto, Prolia |
| Abbvie INC. | $305.12 | 2020-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $265.13 | 2019-2022 |
Show all 90 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $260.54 | 2019-2025 | |
| Exelixis INC. | $256.76 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $237.69 | 2019-2025 | Verzenio, Jaypirca |
| Emd Serono, INC. | $235.15 | 2019-2025 | Bavencio |
| Seagen INC. | $223.04 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $217.93 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Myriad Genetic Laboratories, INC. | $216.86 | 2022-2024 | Myrisk |
| Alexion Pharmaceuticals, INC. | $205.24 | 2019-2025 | Ultomiris |
| Puma Biotechnology, INC. | $199.25 | 2019-2025 | Nerlynx |
| Gilead Sciences, INC. | $177.79 | 2021-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $174.05 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Genmab U.S., INC. | $166.42 | 2021-2024 | Tivdak, Epkinly |
| Ipsen Biopharmaceuticals, INC | $154.97 | 2019-2025 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $154.96 | 2019-2025 | Libtayo |
| Pharmacosmos Therapeutics INC. | $154.69 | 2021-2025 | Monoferric |
| Mirati Therapeutics, INC. | $146.01 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $145.00 | 2023-2025 | Orserdu, Elzonris |
| Jazz Pharmaceuticals INC. | $141.11 | 2022-2025 | |
| Array Biopharma INC | $134.51 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $127.34 | 2019-2025 | |
| Taiho Oncology, INC. | $121.34 | 2024 | |
| Tesaro, INC. | $112.75 | 2019 | |
| Agios Pharmaceuticals, INC. | $108.02 | 2019-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $100.93 | 2021-2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $95.35 | 2021-2024 | Fotivda |
| Kite Pharma, INC. | $92.86 | 2022-2025 | Yescarta |
| Sumitomo Pharma America, INC. | $91.96 | 2023-2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $78.61 | 2019-2025 | Provenge |
| Coherus Oncology, INC. | $78.32 | 2020-2024 | |
| Servier Pharmaceuticals LLC | $75.52 | 2023-2025 | |
| Tempus Ai, INC | $72.16 | 2024-2025 | Xt Cdx |
| Asd Specialty Healthcare, LLC | $70.63 | 2019 | |
| Iovance Biotherapeutics, INC. | $70.32 | 2024-2025 | Amtagvi |
| Octapharma USA, INC. | $59.50 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Morphosys, US INC. | $56.70 | 2022-2024 | Monjuvi |
| Sobi, INC | $54.18 | 2023-2025 | |
| Spectrum Pharmaceuticals INC. | $48.12 | 2023-2025 | Rolvedon |
| Pharmaessentia USA Corporation | $46.62 | 2022-2024 | Besremi |
| Beone Medicines USA, INC. | $45.19 | 2025 | Tevimbra |
| Amag Pharmaceuticals, INC. | $44.26 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $44.11 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Adc Therapeutics America, INC. | $41.25 | 2024 | |
| Immunocore Limited | $39.10 | 2025 | Kimmtrak |
| Tersera Therapeutics LLC | $38.63 | 2025 | Xermelo |
| Geron Corporation | $38.58 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $36.07 | 2024-2025 | Qinlock, Tgct |
| Secura Bio, INC. | $30.85 | 2019 | |
| Apellis Pharmaceuticals, INC. | $28.54 | 2022 | |
| Acceleron Pharma, INC. | $27.61 | 2021 | |
| Invivyd INC | $26.61 | 2025 | Pemgarda |
| Csl Behring | $26.13 | 2019 | |
| Fennec Pharmaceuticals, INC. | $24.97 | 2025 | Fyarro |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Nuvation Bio INC. | $22.35 | 2025 | Ibtrozi |
| Caris Mpi, INC. | $22.22 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $22.00 | 2022 | |
| Immunitybio, INC. | $21.54 | 2024 | |
| Springworks Therapeutics, INC. | $20.24 | 2024 | Ogsiveo |
| G1 Therapeutics, INC. | $19.89 | 2021 | |
| Organon LLC | $18.99 | 2022 | |
| Recordati_rare_diseases_inc. | $18.25 | 2025 | Enjaymo |
| Kyowa Kirin, INC. | $17.77 | 2025 | |
| Cti Biopharma Corp. | $17.41 | 2023 | Vonjo |
| Janssen Scientific Affairs, LLC | $16.48 | 2025 | Darzalex, Tecvayli, Talvey |
| Immunogen, INC. | $16.45 | 2024 | Elahere |
| Fresenius Kabi USA, LLC | $16.03 | 2025 | Stimufend |
| Pharmaand Gmbh | $15.81 | 2025 | Rubraca |
| Tolmar, INC. | $15.81 | 2025 | Eligard, Rubraca |
| Syndax Pharmaceuticals, INC. | $15.13 | 2025 | |
| Advanced Accelerator Applications | $14.81 | 2020 | |
| Novocure INC. | $14.58 | 2025 | Optune Lua (Novottf-200t) |
| Eusa Pharma (US) LLC | $13.26 | 2022 | |
| Epizyme, INC. | $12.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.00 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Darzalex $1,526Keytruda $495Lenvima $486Reblozyl $365Jakafi $314Enhertu $291Xtandi $247Opdivo $223Kisqali $208Myrisk $197Orgovyx $190Imfinzi $180Lynparza $154Epkinly $153Adcetris $148Krazati $146Scemblix $145Imbruvica $133Pluvicto $133Tukysa $131Ibrance $123Lonsurf $121Opdualag $118Monoferric $118Bosulif $108Cabometyx $107Datroway $103Piqray $103Libtayo $98.21Fabhalta $97.32Tivdak $96.94Braftovi $96.55Mektovi $96.55Venclexta $94.11Jaypirca $91.82Verzenio $91.82Monjuvi $90.68Welireg $88.67Xpovio $87.12Fruzaqla $86.24Talvey $84.97Zepzelca $84.74Talzenna $80.34Elrexfio $77.84Orserdu $75.93Trodelvy $74.75Lorbrena $71.67Pyrukynd $71.30Enjaymo $71.25Amtagvi $70.32Elzonris $69.07Pomalyst $68.51Injectafer $68.47Onivyde $65.42Yescarta $62.85Ojjaara $60.74Nubeqa $56.01Vyloy $55.69Xospata $53.98Tibsovo $51.22Vonjo $50.89Rolvedon $48.12Fotivda $47.61Xalkori $45.47Jemperli $45.31Ultomiris $45.20Tevimbra $45.19Polivy $44.32Comirnaty $44.18Paxlovid $44.18Alunbrig $43.25Itovebi $42.15Eliquis $41.43Sarclisa $41.12Rybrevant $40.06Kimmtrak $39.10Xermelo $38.63Rytelo $38.58Cablivi $38.47Lunsumio $36.98Tecentriq $36.79Qinlock $36.07Panzyga $35.69Elahere $35.40Nerlynx $34.64Idhifa $34.06Provenge $33.76Keytruda Qlex $32.69Padcev $32.49Besponsa $32.00Somatuline Depot $31.94Rubraca $31.62Lutathera $30.93Pemazyre $30.69Ayvakit $30.40Rezlidhia $29.92Tavalisse $29.92Loqtorzi $29.39Pemgarda $26.61Zejula $26.40
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noman Rafique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.